Dr. Emtiaz specializes in the development of nanotechnology-driven novel liquid biopsy platforms for the early-stage diagnosis of cancer and infectious diseases.
Dr. Emtiaz Ahmed is currently a Postdoctoral Research Fellow at the Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland (UQ), Australia. Prior to this role, he worked as a Research Officer at the International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) for over five years, focusing on Infectious Disease Research. His work in icddr,b (https://www.icddrb.org/) cantered on studying various gastroenteric pathogens, including viruses, bacteria, and parasites. This involved investigating their incidence and role in gastroenteric diseases, identifying genotypes for vaccine development, studying host factors affecting infection susceptibility, and developing point-of-care diagnostic platforms. Dr. Ahmed's exceptional achievements at icddr,b earned him the prestigious 'University of Queensland Research Training Program (UQ-RTP) Scholarship (2019-2023)' for his PhD studies at UQ, Australia. Dr. Ahmed earned his doctoral degree in 2023 in Biomedical Sciences from the Australian Institute for Bioengineering & Nanotechnology (AIBN), the University of Queensland, receiving the Dean's award for an outstanding PhD thesis. He is a highly skilled biomedical researcher with a strong focus on the development of nanotechnology-based point-of-care technologies for early-stage cancer diagnosis and treatment monitoring. Dr. Ahmed's skills not only benefit cancer and infectious disease diagnosis but also serve as valuable assets for clinicians in monitoring disease prognosis and selecting the most suitable treatments for individual patients, thereby improving treatment outcomes through precision medicine. Early in his scientific career, he has published 11 research articles in highly reputed international journals and garnered over 275 citations (with an h-index of 6), establishing a reputation for significant contributions to the fields of nanotechnologically engineered cancer diagnosis, treatment monitoring, infectious disease diagnosis, vaccine development, and public health research as on March 2024.
Key Publications
Emtiaz Ahmed et al. 2024. A mesoporous gold biosensor to investigate immune checkpoint protein heterogeneity in single lung cancer cells. Biosensors & Bioelectronics (Q1, Impact Factor 12.54). https://doi.org/10.1016/j.bios.2023.115984
Emtiaz Ahmed et al. 2023. A microfluidic liquid biopsy platform to monitor protein biomarker heterogeneity in single circulating therapy-resistance cancer cells. Advanced Sensor Research. https://doi.org/10.1002/adsr.202300059
Emtiaz Ahmed et al. 2020. Nanostructured mesoporous gold electrodes detect protein phosphorylation in cancer with electrochemical signal amplification. Analyst (Q1, Impact Factor 4.616). https://doi.org/10.1039/D0AN01096K
Emtiaz Ahmed* et al. 2018. Giardia/Cryptosporidium QUIK CHEK® assay for rapid point-of-care diagnosis of cryptosporidium diarrhea in children in Bangladesh. Clinical Infectious Diseases (Q1, Impact Factor 9.079). *Joint First Author. https://doi.org/10.1093/cid/ciy372
Kevin M. Koo, Emtiaz Ahmed, and Matt Trau et al. 2023. Nanophotonic immunoarray with electrochemically roughened surfaces for handheld detection of secreted PD-L1 to predict immuno-oncology efficacy. Lab On a Chip (Q1, Impact Factor 7.5). https://doi.org/10.1039/D3LC00523B